Literature DB >> 17975020

Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.

Barry G Shearer1, David J Steger, James M Way, Thomas B Stanley, David C Lobe, Didier A Grillot, Marie A Iannone, Mitchell A Lazar, Timothy M Willson, Andrew N Billin.   

Abstract

The identification of small molecule ligands for the peroxisome proliferator-activated receptors (PPARs) has been instrumental in elucidating their biological roles. In particular, agonists have been the focus of much of the research in the field with relatively few antagonists being described and all of those being selective for PPARalpha or PPARgamma. The comparison of these agonist and antagonist ligands in cellular and animal systems has often led to surprising results and new insights into the biology of the PPARs. The PPARbeta/delta receptor is emerging as an important regulator of energy metabolism, inflammation, and cell growth and differentiation; however, only agonist ligands have been described for this receptor thus far. Here we describe the first report of a PPARbeta/delta small molecule antagonist ligand. This antagonist ligand will be a useful tool for elucidating the biological roles of PPARbeta/delta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975020      PMCID: PMC5419638          DOI: 10.1210/me.2007-0190

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  29 in total

1.  Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

Authors:  Dennis L Sprecher; Christine Massien; Greg Pearce; Andrew N Billin; Itay Perlstein; Timothy M Willson; David G Hassall; Nicolas Ancellin; Scott D Patterson; David C Lobe; Tony G Johnson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

2.  A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.

Authors:  Jennifer Rieusset; Fethi Touri; Liliane Michalik; Pascal Escher; Béatrice Desvergne; Eric Niesor; Walter Wahli
Journal:  Mol Endocrinol       Date:  2002-11

3.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha.

Authors:  H Eric Xu; Thomas B Stanley; Valerie G Montana; Millard H Lambert; Barry G Shearer; Jeffery E Cobb; David D McKee; Cristin M Galardi; Kelli D Plunket; Robert T Nolte; Derek J Parks; John T Moore; Steven A Kliewer; Timothy M Willson; Julie B Stimmel
Journal:  Nature       Date:  2002-02-14       Impact factor: 49.962

4.  A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.

Authors:  W R Oliver; J L Shenk; M R Snaith; C S Russell; K D Plunket; N L Bodkin; M C Lewis; D A Winegar; M L Sznaidman; M H Lambert; H E Xu; D D Sternbach; S A Kliewer; B C Hansen; T M Willson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 5.  WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth.

Authors:  Dingzhi Wang; Jason R Mann; Raymond N DuBois
Journal:  Cell Cycle       Date:  2004-12-06       Impact factor: 4.534

Review 6.  Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.

Authors:  Sadao Takahashi; Toshiya Tanaka; Tatsuhiko Kodama; Juro Sakai
Journal:  Pharmacol Res       Date:  2006-03-29       Impact factor: 7.658

7.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

Authors:  Lisa M Leesnitzer; Derek J Parks; Randy K Bledsoe; Jeff E Cobb; Jon L Collins; Thomas G Consler; Roderick G Davis; Emily A Hull-Ryde; James M Lenhard; Lisa Patel; Kelli D Plunket; Jennifer L Shenk; Julie B Stimmel; Christina Therapontos; Timothy M Willson; Steven G Blanchard
Journal:  Biochemistry       Date:  2002-05-28       Impact factor: 3.162

8.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

Authors:  B R Henke; S G Blanchard; M F Brackeen; K K Brown; J E Cobb; J L Collins; W W Harrington; M A Hashim; E A Hull-Ryde; I Kaldor; S A Kliewer; D H Lake; L M Leesnitzer; J M Lehmann; J M Lenhard; L A Orband-Miller; J F Miller; R A Mook; S A Noble; W Oliver; D J Parks; K D Plunket; J R Szewczyk; T M Willson
Journal:  J Med Chem       Date:  1998-12-03       Impact factor: 7.446

9.  Molecular sensors of estrogen receptor conformations and dynamics.

Authors:  Anobel Tamrazi; Kathryn E Carlson; John A Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2003-08-28

10.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.

Authors:  Marcos L Sznaidman; Curt D Haffner; Patrick R Maloney; Adam Fivush; Esther Chao; Donna Goreham; Michael L Sierra; Christelle LeGrumelec; H Eric Xu; Valerie G Montana; Millard H Lambert; Timothy M Willson; William R Oliver; Daniel D Sternbach
Journal:  Bioorg Med Chem Lett       Date:  2003-05-05       Impact factor: 2.940

View more
  51 in total

Review 1.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

2.  PPARδ prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-κB and inhibition of the PKCα/MEK1/2/ERK1/2/AP-1 pathway.

Authors:  Caroline I Schnegg; Mitra Kooshki; Fang-Chi Hsu; Guangchao Sui; Mike E Robbins
Journal:  Free Radic Biol Med       Date:  2012-03-03       Impact factor: 7.376

3.  The corepressor NCoR1 antagonizes PGC-1α and estrogen-related receptor α in the regulation of skeletal muscle function and oxidative metabolism.

Authors:  Joaquín Pérez-Schindler; Serge Summermatter; Silvia Salatino; Francesco Zorzato; Markus Beer; Piotr J Balwierz; Erik van Nimwegen; Jérôme N Feige; Johan Auwerx; Christoph Handschin
Journal:  Mol Cell Biol       Date:  2012-10-01       Impact factor: 4.272

4.  The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.

Authors:  Teresa Coll; Emma Barroso; David Alvarez-Guardia; Lucía Serrano; Laia Salvadó; Manuel Merlos; Xavier Palomer; Manuel Vázquez-Carrera
Journal:  PPAR Res       Date:  2010-07-27       Impact factor: 4.964

5.  Involvement of Fatty Acid Binding Protein 5 and PPARβ/δ in Prostate Cancer Cell Growth.

Authors:  Elwin Morgan; Padmamalini Kannan-Thulasiraman; Noa Noy
Journal:  PPAR Res       Date:  2010-08-19       Impact factor: 4.964

6.  Protective Effect of Unsaturated Fatty Acids on Palmitic Acid-Induced Toxicity in Skeletal Muscle Cells is not Mediated by PPARδ Activation.

Authors:  Jana Tumova; Lucia Malisova; Michal Andel; Jan Trnka
Journal:  Lipids       Date:  2015-08-09       Impact factor: 1.880

Review 7.  Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases.

Authors:  Mayur Choudhary; Goldis Malek
Journal:  J Biomol Screen       Date:  2016-07-28

8.  PPAR-delta in Vascular Pathophysiology.

Authors:  Nanping Wang
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

9.  Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta.

Authors:  Mattias C U Gustafsson; Deborah Knight; Colin N A Palmer
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

10.  The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta.

Authors:  Yael Riahi; Yoav Sin-Malia; Guy Cohen; Evgenia Alpert; Arie Gruzman; Juergen Eckel; Bart Staels; Michel Guichardant; Shlomo Sasson
Journal:  Diabetes       Date:  2010-01-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.